Lexicon Pharmaceuticals, Inc.LXRXNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)

Oncotelic Therapeutics (OTCMKTS:OTLC - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Profitability This table compares Oncotelic Therapeutics and

globenewswire.com

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The congress is being held March 11-14, 2026, in Barcelona, Spain.

defenseworld.net

Lexicon Pharmaceuticals Q4 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ: LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held March 5, 2026. Management emphasized near-term regulatory and clinical milestones for sotagliflozin in type 1 diabetes and hypertrophic cardiomyopathy (HCM), continued partnering efforts for the chronic pain candidate pilavapadin, and milestone-driven

seekingalpha.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript

globenewswire.com

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments. “The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” said Mike Exton, Ph.D.

globenewswire.com

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m.

globenewswire.com

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

defenseworld.net

Raymond Debbane Purchases 100,000 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) Director Raymond Debbane acquired 100,000 shares of the business's stock in a transaction on Friday, February 20th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $148,000.00. Following the transaction, the director directly owned 1,804,186 shares of the company's

defenseworld.net

GSA Capital Partners LLP Sells 1,627,753 Shares of Lexicon Pharmaceuticals, Inc. $LXRX

GSA Capital Partners LLP lessened its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) by 57.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,202,906 shares of the biopharmaceutical company's stock after selling 1,627,753 shares during the quarter. GSA Capital

globenewswire.com

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “ Series B Convertible Preferred Stock ”). The shares of common stock offered pursuant to the public offering were sold at a public offering price of $1.30 per share and the shares of preferred stock were sold at a price of $65 per share. The offerings closed on February 2, 2026.

defenseworld.net

Invus Global Management, Llc Purchases 1,538,462 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) Director Invus Global Management, Llc bought 1,538,462 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the acquisition, the director

globenewswire.com

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be $41.6 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about February 2, 2026, subject to the satisfaction of customary closing conditions. In addition, Lexicon has granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

globenewswire.com

Lexicon Announces Proposed Public Offering of Common Stock

THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

defenseworld.net

Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX)

NovAccess Global (OTCMKTS:XSNX - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk. Analyst Ratings This is a summary of

globenewswire.com

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026.

globenewswire.com

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the meeting, the FDA raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo.

prnewswire.com

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.

seekingalpha.com

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

globenewswire.com

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m.

globenewswire.com

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and identify what more can be done to benefit patients and society at large.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance